Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04137536 · ClinicalTrials.gov registry record · Phase 1

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

A Phase 1 study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 1
Development phase
7
Enrollment target
2
Study locations

NCT04137536: Active Phase 1 study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04137536 is a Phase 1 study of Pancreatic Cancer and Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 7 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04137536, a Phase 1 study of Pancreatic Cancer and Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
7 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.

Primary Outcome

The NCI CTEP CTCAE v4.0 will be used.

Conditions Studied

Pancreatic Cancer Pancreatic Adenocarcinoma Pancreatic Neoplasms Advanced Pancreatic Cancer

Interventions

  • DRUG anti-EGFR-bispecific antibody armed activated T-cells

Study Locations (2)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Virginia

  • University of Virginia (Specimen Analysis) - Charlottesville

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2019-10-17
Est. Completion 2026-04
Phase Phase 1
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT04137536 still lists

NCT04137536 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower).

The record links to 4 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which anti-EGFR-bispecific antibody armed activated T-cells is the first listed.

NCT04137536 reports a single indexed study location in New York, Virginia.

Frequently Asked Questions

What is clinical trial NCT04137536 about?

NCT04137536 is a clinical study titled "A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer". The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.

What is the current status of trial NCT04137536?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-10-17. Estimated completion is 2026-04.

What conditions does trial NCT04137536 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Neoplasms, Advanced Pancreatic Cancer.

What interventions are being tested in trial NCT04137536?

The interventions under investigation include: anti-EGFR-bispecific antibody armed activated T-cells (DRUG).

Who is sponsoring clinical trial NCT04137536?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04137536 being conducted?

This trial has 2 study locations across New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04137536's enrollment target sits among peer trials

7 272nd of 278 higher than 7 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04137536, the US trial registry maintained by the National Library of Medicine. NCT04137536 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.